A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study.

Abstract

PURPOSE:

To evaluate the efficacy, effect profile, and safety of dexamethasone implant on diabetic macular edema (DME) in a real-life setting, further comparing results by DME duration, previous treatment status, and diabetic control.

DESIGN:

A multicenter, retrospective cohort of 340 DME eyes of 287 patients from 25 clinical sites from 8 countries.

METHODS:

Data were analyzed in 2 perspectives: per injection, in which all measurements were grouped and baseline was defined as the day of injection, and thus the pharmacodynamics of single injections could be assessed; and injection series, defined as 2 or more injections with 3 to 6 months between injections analyzing the outcome 3 to 6 months after the last injection.

MAIN OUTCOME MEASURES:

Primary outcome was improvement of 15 or more letters in best-corrected visual acuity (BCVA) from baseline. Secondary outcomes included improvement of 10 letters or more in BCVA, change in central macular thickness (CMT), and time to maximum improvement and safety.

RESULTS:

Overall, 762 injections were administered to 340 eyes of 287 patients. Injection series analysis included 171 series in 171 eyes of 150 patients, for a total of 444 injections, with a mean follow-up of 1.7±0.8 years. Of the 762 injections analyzed per injection, 22.7% achieved a 15-letter or more improvement, and 37.8% achieved a 10-letter or more improvement. Mean time to peak improvement was 81.9±39.7 days. Mean maximum change in CMT was -174±171 μm. Overall, 7.6% lost 15 or more letters. More eyes with early DME gained 10 or more letters and fewer eyes lost 10 or more letters compared with eyes with late DME (47.4% vs. 33.9% [P = 0.001] and 8.2% vs. 13.5% [P = 0.029], respectively). Patients with controlled diabetes showed greater CMT reduction (P = 0.0002). A higher percentage of treatment-naive patients gained 10 or 15 letter or more in BCVA (P = 0.001 and P = 0.006, respectively). Intraocular pressure elevation of more than 25 mmHg was found following 7.9% of injections; no endophthalmitis was reported.

CONCLUSIONS:

Dexamethasone implant is an effective and safe treatment for DME. Peak improvement was achieved 3 months after injection and dissipated thereafter. Clinicians and providers may consider shortening treatment intervals.

• Authors: Amir Rosenblatt, Patricia Udaondo, José Cunha-Vaz, Sobha Sivaprasad, Francesco Bandello, Paolo Lanzetta, Laurent Kodjikian, Michaella Goldstein, Zohar Habot-Wilner, Anat Loewenstein, ARTES Study Group
• Journal: Ophthalmology (Ophthalmology) Vol. 127 Issue 3 Pg. 377-393 (03 2020) ISSN: 1549-4713 [Electronic] United States
• PMID: 31932090 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Drug Implants
• Glucocorticoids
• Dexamethasone

Topics

• Adult
• Aged
• Dexamethasone (administration & dosage)
• Diabetic Retinopathy (drug therapy)
• Drug Implants (therapeutic use)
• Female
• Glucocorticoids (administration & dosage)
• Humans
• Intravitreal Injections
• Macular Edema (drug therapy)
• Male
• Middle Aged
• Retrospective Studies
• Visual Acuity